ABOUT THE SYMPOSIUM

The 2nd ADVANCE-ID Network Symposium will be held on 18-19 February 2025 at the Grand Copthorne Waterfront Hotel, Singapore. This event, organized by the ADVANCE-ID Network based at the National University of Singapore’s Saw Swee Hock School of Public Health (SSHSPH), will focus on the growing global health threat of antimicrobial resistance (AMR). The symposium will bring together experts, clinicians, researchers, and policymakers from across Asia and beyond, providing a critical platform for sharing innovative strategies and research to combat AMR.

AMR poses an increasing threat to global health by undermining decades of medical progress, complicating treatment options, and straining healthcare systems. In line with the United Nations’ mandate for international action, the symposium’s theme, “Translating Clinical Research into Strategies for Targeting AMR Treatment, Detection, and Prevention,” underscores the urgent need for collaborative and evidence-based solutions.

Participants will engage with leading experts in AMR surveillance, infection control, and antibiotic stewardship through dynamic sessions, case studies, and expert panels. Attendees will gain actionable insights into the latest research and its real-world applications in AMR management. This symposium will foster knowledge exchange and promote impactful collaborations that align with the UN’s global health agenda, creating an invaluable opportunity to forge partnerships and develop solutions that contribute to a healthier, more resilient global community​.

ABOUT THE ORGANISERS

2nd Advance-ID_Web-20

The ADVANcing Clinical Evidence in Infectious Diseases (ADVANCE-ID) Network is a global network for infectious disease clinical studies. Our aim is to conduct rapid, cost-effective randomised controlled trials to deliver relevant and high quality evidence to guide clinical practice. We hope to achieve this vision through equity (shared ownership), sustainability (build long-term capacity and trust) and engagement of key stakeholders (including clinicians, scientists, governments, industry).

2nd Advance-ID_Web-19

Building upon decades of experience in research, training and practice in epidemiology and public health, the Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore, was established in October 2011 as Singapore’s first and only full-fledged national public health tertiary education institution. The School is also a member of the National University Health System (NUHS).

The School aims to continually foster healthier communities in Singapore and the region, and impact public health programmes and policies through its robust educational programmes and translational cross-disciplinary research work on cohort studies and life course epidemiology, infectious disease research, health technology assessments, health promotion, workplace safety and health, health systems evaluation and health services research. An interdisciplinary approach, augmented by rigorous training, applicable research and regional partnerships, places SSHSPH at the forefront of public health knowledge discovery and practice in Asia.

The School actively collaborates with many partners including the London School of Hygiene & Tropical Medicine, Karolinska Institutet, Harvard School of Public Health and University of Michigan School of Public Health. Its flagship programme, the Master of Public Health (MPH) degree, attracts students from a wide range of disciplines from within Singapore and throughout the region.

AT A GLANCE

Programme At A Glance 7c

DETAILED PROGRAMME

Day 1 P1
Day 1 P2v2
Day 2 v2

Our esteemed speakers at the symposium include:

Prof. Direk Limmathurotsakul – Mahidol Oxford Tropical Medicine Research Unit, Thailand, a prominent expert in AMR surveillance and data utilization, particularly in tropical medicine, with extensive experience across Southeast Asia.

Prof. Xiao Yonghong – First Affiliated Hospital, Zhejiang University, China, known for his significant contributions to antibiotic stewardship and infection control, specifically within high-risk regions in Asia.

Prof. Trisha Peel – Monash University, Australia, a respected leader in infection prevention and antibiotic stewardship, focusing on preventing post-surgical infections and enhancing global AMR management.

Prof. Gan Yunn Hwen – National University of Singapore, a leading researcher in microbiome studies, focusing on gut colonization resistance against AMR pathogens. Her research includes multidrug-resistant enteric bacteria, transmission of resistance plasmids in Gram-negative bacteria, and bacterial sensing of host environments. 

Prof. Darshini Ayton– Monash University, Australia, has a strong background in health and social care research, utilizing various methodological approaches, including qualitative research and clinical registries. She is experienced in randomized controlled trials, consumer and community involvement, and implementation science, which enhances the practical application of research findings in healthcare settings.

TRAVEL AND ACCOMMODATION

grand_copthorne-1

The 2nd Advance-ID Network Symposium will take place at the Grand Copthorne Waterfront Hotel Singapore. The hotel is a 5-star luxury hotel overlooking the historic Singapore River, tucked away from the hustle-and-bustle of city life. It’s located ideally near the CBD (Central Business District) and popular waterfront spots Robertson Quay, Clarke Quay and Boat Quay.

Picture1-1

The Symposium will be held at the Grand Ballroom (Level 4). Grand Copthorne Waterfront presents an impressive 6,200 square meters of meetings and events venues, overlooking scenic views of the picturesque Singapore River and is fully equipped with state-of-art meeting aids and world-class audio-visual facilities.

Delegates who wish to book rooms at the Hotel may do so using our registration portal here.

REGISTRATION

2nd Advance-ID_Reg_Table

^ For "Government Agencies / Healthcare / Academic Institution" Discount, please register using your corporate email and upload image of staff pass or a similar supporting document as proof.

* "Low to Lower-Middle Income Countries" - Delegates from these countries can select the "Low to Lower-Middle Income Countries" category under "Participant Type" on the payment page, after entering their details (View WorldBank Listing here).

 

2nd Advance-ID_Website_Register Now Button (1)

OUR PARTNERS

COLLABORATORS

BIOVERSYS-02
CMCVELLORE
COMRU-01
Duke-NUS-01
GARDP
MORU_03
LKCSOM-01
NCID-01
YLLSOM-01
OUCRU-02
PREPARE-03
SCRI-01
SCRN-01

SPONSORS

AEROGEN
BD
BIOMERIEUX-01
CSI
GCCS
ILLUMINA
MSD
TAIMEI-02

SPONSORS PROFILE

Aerogen
As the world leader in acute care aerosol drug delivery, Aerogen is proud to sponsor the ADVANCE-ID Symposium. With over 25 years of experience, 300 international patents and 200+ clinical papers, Aerogen vibrating mesh nebuliser technology has been used to treat 25 million patients in 75 countries worldwide.

From critical care to emergency care, and across multiple ventilated and non-ventilated therapies, Aerogen facilitates aerosol drug delivery at every stage of the patient’s respiratory journey.
BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.

BD has more than 70,000 employees and a presence in virtually every country around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com
bioMerieux
A world leader in the field of in-vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries through a large network of distributors. bioMérieux provides diagnostic solutions (systems, reagents, software and services) that determine the origin of a disease to improve the health of patients. World leader in microbiology, specialized in immunoassays and leading pioneer in the syndromic molecular approach, the Company is committed worldwide on major public health issues in the field of infectious disease, such as antimicrobial resistance, sepsis and respiratory infections.
https://www.biomerieux.com/
CSI Medical Research
Founded in 2017, CSI Medical Research is a leading regional CRO in Southeast Asia, known for our expertise in clinical trial execution. In 2024, CSI MR was acquired by ClinChoice, expanding our global presence across 30+ countries. By 2026, we aim to be Southeast Asia’s most trusted CRO, providing cost-effective, high-quality clinical trial services across the Asia Pacific, with a focus on delivering high-quality research results and improving patient outcomes.
GCCS
GCCS is a Specialty Courier and Logistics service provider focusing on time critical and temperature sensitive shipments in the Biopharma, Healthcare and Life Sciences industry. With expertise in cold-chain logistics and unequalled passion in quality, our dedicated team has helped our clients overcome timelines and navigate regulatory compliance, enabling them to focus on their core competence.
Illumina
At Illumina, our mission is to improve human health by unlocking the power of the genome. Our sequencing by synthesis chemistry is used to generate high-accuracy DNA and RNA sequence data around the globe. The innovative sequencing products we provide are also bringing genomics to the forefront of public health surveillance, providing unprecedented speed and scale to infectious disease monitoring and pandemic response.

These tools provide a framework for advancing pathogen detection within a population, improving rapid responses to ongoing outbreaks, and supporting research towards the discovery of emerging infectious agents.
MSD
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.

We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
Taimei Technology
Taimei Technology is a leading provider of digital solutions for clinical research and pharmacovigilance, delivering AI-powered SaaS products and Intelligent collaboration platforms that significantly enhance the efficiency and quality of drug R&D processes

CONTACT US

C2 Creative Communications is the appointed MICE partner for 2nd ADVANCE-ID Network Symposium.
For assistance, please contact the Secretariat:

Email: chyau@csquare-creative.com
Hotline: +65 6270-0303
Operating hours: 10:00 – 5:00pm (GMT +8), Monday to Friday, excluding Public Holidays

National University of Singapore. All Rights Reserved

Logo-Lockup

Copyright © ADVANCE-ID. All rights reserved.

ADVANCE-ID
Saw Swee Hock School of Public Health
National University of Singapore

Tahir Foundation Building
National University of Singapore
12 Science Drive 2, #10-01, Singapore 117549
+65 6516 4988